Neratinib (Nerlynx) is an oral tyrosine kinase inhibitor (TKI) that irreversibly inhibits HER2 and EGFR kinases (epidermal growth factor receptor), specifically designed to target HER2-positive BC. Here, ERBB2 is linked to breast cancer.